Buprenorphine and naloxone interactions in methadone maintenance patients

被引:46
作者
Mendelson, J
Jones, RT
Welm, S
Brown, J
Batki, SL
机构
[1] Drug Dependence Research Center, Department of Psychiatry, Univ. of California, San Francisco, San Francisco, CA
[2] Langley Porter Psychiatric Institute, Univ. of California, San Francisco, San Francisco, CA 94143-0984
关键词
buprenorphine; naloxone; methadone; opiate antagonist; intravenous administration; opiate withdrawal;
D O I
10.1016/S0006-3223(96)00266-1
中图分类号
Q189 [神经科学];
学科分类号
071006 ;
摘要
Buprenorphine is undergoing clinical trials for the treatment of opiate addiction, Although the abuse liability of sublingual buprenorphine is low, reports of intravenous abuse have appeared, This study describes the physiologic and subjective effects of intravenously administered buprenorphine and naloxone given alone and in combination to methadone-maintained patients (40-60 mg/day). On four separate occasions at least 1 day apart, 6 subjects were administered either 0.2 mg buprenorphine, 0.1 mg naloxone, 0.2 mg buprenorphine and 0.1 mg naloxone in combination, or placebo, One male subject quit the experiment after three sessions because of excessive opiate withdrawal. Buprenorphine produced no significant physiologic or subjective effects. Naloxone produced marked opiate withdrawal symptoms, Buprenorphine in combination with naloxone produced characteristic physiologic and subjective opiate antagonist-like symptoms and signs, The parenteral abuse potential of the buprenorphine and naloxone combination is discussed. (C) 1997 Society of Biological Psychiatry.
引用
收藏
页码:1095 / 1101
页数:7
相关论文
共 24 条
[1]  
*AM PSYCH ASS APA, 1987, DIAGN STAT MAN MENT, P167
[2]  
BICKEL WK, 1988, J PHARMACOL EXP THER, V247, P47
[3]   BUPRENORPHINE KINETICS [J].
BULLINGHAM, RES ;
MCQUAY, HJ ;
MOORE, A ;
BENNETT, MRD .
CLINICAL PHARMACOLOGY & THERAPEUTICS, 1980, 28 (05) :667-672
[4]   USE OF BUPRENORPHINE IN THE TREATMENT OF OPIOID ADDICTION .2. PHYSIOLOGIC AND BEHAVIORAL-EFFECTS OF DAILY AND ALTERNATE-DAY ADMINISTRATION AND ABRUPT WITHDRAWAL [J].
FUDALA, PJ ;
JAFFE, JH ;
DAX, EM ;
JOHNSON, RE .
CLINICAL PHARMACOLOGY & THERAPEUTICS, 1990, 47 (04) :525-534
[5]   ANALYSIS OF EPIDEMIOLOGICAL DATA ON AGONIST-ANTAGONIST ANALGESICS [J].
GHODSE, AH .
DRUG AND ALCOHOL DEPENDENCE, 1987, 20 (04) :375-383
[6]  
Gilman AG, 1990, GOODMAN GILMANS PHAR
[7]   MORPHINE COMBINED WITH DOXAPRAM OR NALOXONE - STUDY OF POSTOPERATIVE PAIN RELIEF [J].
GUPTA, PK ;
DUNDEE, JW .
ANAESTHESIA, 1974, 29 (01) :33-39
[8]  
JASINSKI DR, 1978, ARCH GEN PSYCHIAT, V35, P501
[9]   SUBLINGUAL VERSUS SUBCUTANEOUS BUPRENORPHINE IN OPIATE ABUSERS [J].
JASINSKI, DR ;
FUDALA, PJ ;
JOHNSON, RE .
CLINICAL PHARMACOLOGY & THERAPEUTICS, 1989, 45 (05) :513-519
[10]   A CONTROLLED TRIAL OF BUPRENORPHINE TREATMENT FOR OPIOID DEPENDENCE [J].
JOHNSON, RE ;
JAFFE, JH ;
FUDALA, PJ .
JAMA-JOURNAL OF THE AMERICAN MEDICAL ASSOCIATION, 1992, 267 (20) :2750-2755